$5.73
+14%Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
HIND • NASDAQ
| Vyome Holdings, Inc. Income Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 | Dec 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
8M | 8.7M | 11.2M | 13.6M | 11.3M | 15.1M | 606.7K | 1.3M | 786.7K | 292K | 0.0 | 0.0 | 312K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(2.9M) | (3.1M) | (4.4M) | (5.3M) | (5M) | (5.8M) | (164.3K) | (936.4K) | (431.5K) | (125K) | (0.0) | (0.0) | (232K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
5.1M | 5.5M | 6.8M | 8.3M | 6.3M | 9.3M | 442.4K | 350.8K | 355.2K | 167K | 0.0 | 0.0 | 80K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||||||||
(11.7M) | (20.2M) | (33.9M) | (36.1M) | (18.7M) | (25.2M) | (25M) | (31.8M) | (23.2M) | (28M) | (25.6M) | (24.7M) | (22.6M) | (25.3M) | (16.2M) | (24.2M) | (36.3M) | (28M) | (18.1M) | (11.2M) | |
(9.9M) | (17.9M) | (31.3M) | (33.6M) | (15.2M) | (22.1M) | (19.3M) | (26M) | (18M) | (19.9M) | (14.6M) | (13.7M) | (12M) | (8.6M) | (7.7M) | (8.6M) | (8.6M) | (7M) | (3.8M) | (2.3M) | |
(1.8M) | (2.3M) | (2.5M) | (2.5M) | (3.5M) | (3.1M) | (5.7M) | (5.8M) | (5.2M) | (8.1M) | (11M) | (11.1M) | (10.7M) | (16.7M) | (8.5M) | (15.6M) | (27.7M) | (21.1M) | (14.4M) | (8.8M) | |
-6.7M | -14.6M | -27.1M | -24.9M | -12.5M | -15.9M | -38.5M | -31.4M | -22.8M | -27.9M | -25.6M | -24.7M | -22.5M | -25.3M | -16.2M | -24.2M | -36.3M | -28M | -18.1M | -11.2M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (113K) | (832K) | (2M) | (451K) | (12K) | (3.9K) | (4.1M) | (939.2K) | (530.2K) | (932.4K) | (901.8K) | (722.9K) | (1.3M) | (4.1M) | (2.7M) | (1.6M) | (710.1K) | (181.2K) | |
14K | 26K | -113K | -832K | -2M | -451K | -12K | -2.8K | -4.1M | -937.4K | -526.9K | -926.6K | -892K | -710.6K | -1.3M | -4M | -1.6M | -92.3K | 425.7K | -71.3K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -10.6K | -652.0 | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
637K | 4M | -19.5M | -38.5M | -9.4M | -50.6M | -167.7K | -1.4M | -565.2K | 2.4M | -535.7K | -1M | -911.1K | -30.1K | -1.2M | -7.7M | -21.9K | -456.9K | 5.6K | 8.4K | |
-7.1M | -11.3M | -46.6M | -63.4M | -21.8M | -75.1M | -38.7M | -36.1M | -23.4M | -25.5M | -26.1M | -25.8M | -23.5M | -25.3M | -17.3M | -31.9M | -36.3M | -28.5M | -18.1M | -11.1M | |
NET INCOME | ||||||||||||||||||||
(39K) | (52K) | -380K | -274K | -181K | -893K | -3.4M | -2.3M | (0.0) | -2.6M | (347.1K) | (872.4K) | -227K | (740.7K) | (0.0) | (0.0) | (1.6M) | (549.2K) | -431.3K | (62.9K) | |
-7.1M | -11.4M | -46.2M | -63.1M | -21.6M | -74.2M | -81.2M | -33.8M | -23.4M | -25.5M | -26.1M | -25.8M | -23.5M | -26M | -17.3M | -31.9M | -37.9M | -28.6M | -17.7M | -11.2M |
HIND - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | November 19, 2025 | November 18, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
S-3 S-3 N/A | November 06, 2025 | November 06, 2025 | ||
8-K 8-K 2025 N/A | October 30, 2025 | October 28, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | October 06, 2025 | October 28, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 03, 2025 | September 29, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | September 12, 2025 | September 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 02, 2025 | September 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 20, 2025 | August 18, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 19, 2025 | August 13, 2025 | 2025 |
Continue your HIND research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.